Welcome to CSNpharm! For Research Use Only!

Bcr-Abl

Bcr-Abl

Cat. No. Product Name CAS No. Information
CSN15826 ZM 306416   690206-97-4 ZM-306416 is an inhibitor of VEGFR (Flk-1 or KDR) and Flt with IC50 of 100 nM and 2 μM. It also shows inhibition activity against Src and Abl with IC50 values of 0.33μM and 1.3μM, respectively.
CSN16658 Degrasyn 856243-80-6 WP1130 is a selective small molecular deubiquitinase USP5 UCH-L1 USP9x USP14 and UCH37 inhibitor and a BcrAbl destruction pathway activator with an IC50 of 18 M for K562 cells
CSN28459 SIAIS178 2376047-73-1 SIAIS178 is a potent and selective BCR-ABL degrader based on PROTAC technology with an IC50 of 24 nM. SIAIS178 causes effective degradation of BCR-ABL protein by recruiting Von Hippel-Lindau (VHL) E3 ubiquitin ligase. SIAIS178 has anticancer activity.
CSN18591 Radotinib   926037-48-1 Radotinib is a selective BCR-ABL1 inhibitor with IC50 of 34 nM also inhibits platelet-derived growth factor receptor PDGFR is used to treat cancers and Chronic Myeloid Leukemia
CSN22517 N-Deshydroxyethyl Dasatinib 910297-51-7 PROTAC Bcr-Abl-binding moiety 1 is a Dasatinib-based warhead ligand for conjugation reactions of PROTAC targeting on Bcr-Abl.
CSN23049 PPY-A 875634-01-8 PPY A is a potent inhibitor of T315l mutant and wild-type Abl kinases with IC50s of 9 and 20 nM, respectively.
CSN12687 Ponatinib 943319-70-8 Ponatinib is a potent multi-target inhibitor of Abl PDGFR VEGFR2 FGFR1 and Src with IC50 of 037 nM 11 nM 15 nM 22 nM and 54 nM respectively
CSN21067 Ponatinib hydrochloride 1114544-31-8 Ponatinib is a multi-targeted kinase inhibitor with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src respectively.
CSN32501 Vamotinib 1416241-23-0 PF-114 is a Bcr-Abl1 inhbitor.
CSN16663 NVP-BHG712 940310-85-0 NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition and also shows activity against c-Raf c-Src and c-Abl with IC50 of 0395 M 1266 M and 1667 M respectively
CSN11559 Nilotinib   641571-10-0 Nilotinib is a Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells
CSN12295 Nilotinib monohydrochloride monohydrate   923288-90-8 Nilotinib HCl is a Bcr-Abl inhibitor with IC50 < 30 nM.
CSN12740 Lyn-IN-1 887650-05-7 Lyn-IN-1 is a potent and selective dual Bcr-AblLyn inhibitor with potential antineoplastic activity it is an orally bioavailable 2-phenylaminopyrimidine derivative
CSN17632 Olverembatinib   1257628-77-5 GZD824 is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl WT and Bcr-Abl T315I with IC50 of 034 and 068 nM respectively
CSN18803 Olverembatinib dimesylate 1421783-64-3 GZD824 dimesylate is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl WT and Bcr-Abl T315I with IC50 of 034 nM and 068 nM respectively
CSN15689 GNF-7 839706-07-9 GNF-7 inhibits Bcr-Abl WT and Bcr-Abl T315I with IC50 of 133 nM and 61 nM respectively
CSN12398 GNF-5   778277-15-9 GNF-5 is a selective non-ATP competitive inhibitor of Bcr-Abl with IC50 of 220 nM its an analogue of GNF-2 with improved pharmacokinetic properties
CSN13825 GNF-2 778270-11-4 GNF-2 is a highly selective non-ATP competitive inhibitor of oncogenic Bcr-Abl activity IC50 014 M
CSN25549 GMB-475 2490599-18-1 GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 reduced viability and increased apoptosis in primary CML CD34+ cells, with no effect on healthy CD34+ cells at identical concentrations.
CSN17178 Flumatinib mesylate 895519-91-2 Flumatinib mesylate a derivative of imatinib is a multi-kinase inhibitor with IC50 Values of 12 nM 3076 nM and 2662 nM for c-Abl PDGFR and c-Kit respectively
CSN18538 Flumatinib 895519-90-1 Flumatinib is a multi-kinase inhibitor with IC50 Values of 12 nM 3076 nM and 2662 nM for c-Abl PDGFR and c-Kit respectively
CSN16096 DPH 484049-04-9 DPH is a potent cell permeable c-Abl activator which displays potent enzymatic and cellular activity in stimulating c-Abl activation
CSN13733 Rebastinib 1020172-07-9 DCC-2036 is a conformational control Bcr-Abl inhibitor for Abl1 WT and Abl1 T315I with IC50 of 08 nM and 4 nM also inhibits SRC LYN FGR HCK KDR FLT3 and Tie-2
CSN12769 Dasatinib monohydrate   863127-77-9 Dasatinib is a potent and multi-targeted inhibitor that targets Abl Src and c-Kit with IC50 of 1 nM 08 nM and 79 nM respectively
CSN16497 Dasatinib   302962-49-8 Dasatinib is a potent and dual Abl/ Src inhibitor IC50 of < 1 nM/0.8 nM respectively and also inhibits c-Kit (WT)/c-Kit (D816V) with IC50 of 79 nM/37 nM.
CSN18475 Dasatinib hydrochloride 854001-07-3 Dasatinib HCl is a potent and dual Abl/ Src inhibitor IC50 of < 1 nM/0.8 nM respectively and also inhibits c-Kit (WT)/c-Kit (D816V) with IC50 of 79 nM/37 nM.
CSN28518 SNIPER(ABL)-039 2222354-29-0 DAS-IAP is a novel PROTAC targeting drug-resistant BCR-ABL.
CSN12423 Danusertib 827318-97-8 Danusertib is a pyrrolo-pyrazole and small molecule Aurora kinases inhibitor with IC50 of 13, 79, and 61 nM for Aurora A, B, and C, respectively. It is modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc.
CSN27382 CZC-8004 916603-07-1 CZC-8004 is a pan-kinase inhibitor and binds a range of tyrosine kinases, including ABL kinase.
CSN15883 Agerafenib 1188910-76-0 CEP-32496 is an inhibitor of BRAF V600E (IC50 14 nM), WT (IC50 34 nM) and c-Raf (IC50 39 nM). It also exhibits certain inhibitory activity against Abl-1, c-Kit, Ret, PDGFR and VEGFR2.
CSN26601 BCR-ABL-IN-3 2240191-12-0 BCR-ABL-IN-3 is a potent and irreversible Bcr-Abl inhibitor with an IC50 of ≤100 nM for Ba/F3Bcr-AblT3151. BCR-ABL-IN-3 has anti-cancer activity[1].
CSN21248 BCR-ABL-IN-1 188260-50-6 BCR-ABL-IN-1 is an inhibitor of BCR-ABL tyrosine kinase with a pIC50 of 646 and may be used in the research of chronic myelogenous leukemia
CSN19120 BBT594 882405-89-2 BBT594 is a potentreceptor tyrosine kinase RET inhibitor, used for cancer treatment.
CSN19269 Bafetinib 859212-16-1 Bafetinib is a potent and selective dual Bcr-AblLyn inhibitor with IC50 of 5.8 nM19 nM in cell-free assays, does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and c-Kit.
CSN18365 AST 487 630124-46-8 AST-487 is a RET kinase inhibitor with IC50 of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits Flt-3 with IC50 of 520 nM. AST487 also inhibits RET,KDR,c-KIT,and c-ABL kinase with IC50 values below 1 μM.
CSN18872 Asciminib 1492952-76-7 Asciminib is a potent and selective allosteric Bcr-Abl inhibitor and inhibits BaF3 cells grown with an IC50 of 025 nM
CSN29430 Vodobatinib 1388803-90-4
<< PREV 1 2 NEXT >>